SEC Company Response from MetaVia Inc. (MTVA) (CIK 0001638287) (MTVA) — Jun 20, 2016
MetaVia Inc. (MTVA) (CIK 0001638287)
Date: June 20, 2016 · CIK: 0001638287 · Accession: 0001104659-16-128347
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-210815
Letter
June 20, 2016
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Washington, D.C. 20549
Attention: Suzanne Hayes
Joshua Samples
Lilyanna Peyser
Sharon Blume
Sasha Parikh
Re: Gemphire Therapeutics Inc.
Registration Statement on Form S-1
File No. 333-210815
Acceleration Request
Requested Date:
June 22, 2016
Requested Time:
4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Gemphire Therapeutics Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-210815) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes each of Phillip D. Torrence, Meredith Ervine and Gabrielle L. Sims of Honigman Miller Schwartz and Cohn LLP, counsel to the Company, to make such request on its behalf.
The Company hereby acknowledges that:
· should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please confirm the effectiveness of the Registration Statement with Phillip D. Torrence of Honigman Miller Schwartz and Cohn LLP by telephone at (269) 337-7702.
[Signature page follows]
****
Sincerely,
GEMPHIRE THERAPEUTICS INC.
Show Raw Text
CORRESP 1 filename1.htm June 20, 2016 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Suzanne Hayes Joshua Samples Lilyanna Peyser Sharon Blume Sasha Parikh Re: Gemphire Therapeutics Inc. Registration Statement on Form S-1 File No. 333-210815 Acceleration Request Requested Date: June 22, 2016 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Gemphire Therapeutics Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-210815) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes each of Phillip D. Torrence, Meredith Ervine and Gabrielle L. Sims of Honigman Miller Schwartz and Cohn LLP, counsel to the Company, to make such request on its behalf. The Company hereby acknowledges that: · should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please confirm the effectiveness of the Registration Statement with Phillip D. Torrence of Honigman Miller Schwartz and Cohn LLP by telephone at (269) 337-7702. [Signature page follows] **** Sincerely, GEMPHIRE THERAPEUTICS INC. /s/ MINA SOOCH Mina Sooch President, Chief Executive Officer and Treasurer cc: Phillip D. Torrence, Honigman Miller Schwartz and Cohn LLP Meredith Ervine, Honigman Miller Schwartz and Cohn LLP Gabrielle L. Sims, Honigman Miller Schwartz and Cohn LLP Divakar Gupta, Cooley LLP Charles S. Kim, Cooley LLP Siana E. Lowrey, Cooley LLP